Skip to content
Clinical Trials – home

Endomed s.r.o.

Verified siteinfo

Slovakia Americka Trieda 19, Sidlisko Tahanovce, 040 13 Kosice, Slovakia

  • 17 trials recruiting
  • Colitis ulcerative · Crohn's disease · Acute haemorrhagic ulcerative colitis
  • Adults and children

About Specializations

Endomed s.r.o. in Kosice, Slovakia specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Acute haemorrhagic ulcerative colitis, Coeliac disease, and other specialisations. This site conducts important research.

Main research areas of the site

Digestive System Diseases

At Endomed s.r.o. in Kosice, clinical research in Digestive System Diseases focuses mainly on inflammatory bowel disease, including Crohn’s disease, ulcerative colitis, coeliac disease, and related gastrointestinal disorders. The trials are designed to test new treatments, compare treatment options, and better understand how these conditions affect the digestive tract.

  • Studies in Crohn’s disease and ulcerative colitis aimed at improving symptom control and long-term disease management
  • Research on coeliac disease and eosinophilic esophagitis exploring immune-related gut inflammation and mucosal healing
  • Clinical evaluation of new therapies for inflammatory bowel disease to measure remission, healing, and overall treatment effectiveness

Overall, this therapeutic area is centered on finding safer and more effective options for people living with chronic gastrointestinal inflammation and immune-driven digestive disorders.

Immune System Diseases

The Immune System Diseases research portfolio at Endomed s.r.o. includes trials for conditions where the immune system drives ongoing inflammation, especially Crohn’s disease, ulcerative colitis, and eosinophilic esophagitis. These studies aim to improve how immune-targeted treatments work and to assess whether they can reduce inflammation and support lasting disease control.

  • Trials in moderately to severely active Crohn’s disease assessing new immune-based therapies for remission and response
  • Research in moderately to severely active ulcerative colitis focused on treatment effectiveness, maintenance of benefit, and symptom relief
  • Studies in eosinophilic esophagitis and non-responsive celiac disease examining immune activity in the gut and esophagus

These projects reflect a strong emphasis on immune-mediated disease, with the goal of advancing targeted approaches that may better match the needs of patients with chronic inflammatory conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Americka Trieda 19, Sidlisko Tahanovce040 13 KosiceSlovakia
Recruiting now
17 trials
Conditions studied
6
Partner status
Verified site

More sites in KosiceSlovakia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

38 clinical trials

Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

Investigational
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study testing duvakitug for patients with moderately to severely active ulcerative colitis

Investigational
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Ro7790121
  • Sponsor:F. Hoffmann-La Roche AG

Crohn's disease

Recruiting

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Morf-057
  • Sponsor:Morphic Therapeutic Inc.

Crohn's disease

Recruiting

Study on the Long-Term Effects and Safety of Mirikizumab for Patients with Crohn's Disease

InvestigationalNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.